Introduction {#s1}
============

The astonishing rise in obesity prevalence and the marked decline in perioperative mortality over the previous two decades have both contributed to the growing popularity of bariatric surgery. In the period from 1998 to 2003, the number of bariatric procedures performed increased 10-fold [@pone.0032506-Santry1], and in 2009 alone, 220,000 bariatric surgeries were performed in the United States and Canada [@pone.0032506-American1]. Despite the clinical benefits, the potential for serious and costly major adverse events deters many patients and payers from utilizing its advantages.

Bariatric surgery is safe with a 0.15% to 0.5% 30-day mortality rate [@pone.0032506-Buchwald1]--[@pone.0032506-Zingmond1], however an appreciable proportion of patients suffer at least one major adverse event within the first 30 days following either Roux-en-Y gastric bypass (RYGB) or adjustable gastric banding (AGB) that results in hospital readmission. A hospital readmission increases the average 180-day cost of a bariatric operation from approximately \$27,000 to \$65,000 [@pone.0032506-Encinosa1]. In response to the high costs of hospital readmission, in 2008 the National Quality Forum indicated that hospital readmission rates would be a central factor in evaluating hospital performance with penalties being levied against hospitals with high readmission rates.

Identifying patient and surgical factors that increase perioperative risk of readmission would improve both the tenability of bariatric surgery for patients and the cost-effectiveness for payers. Comprehensive assessment of patient risks a priori would provide physicians with a framework for either tailoring the selection of intervention or identifying patients most in need of enhanced education or monitoring post-operatively, which could, in turn, reduce the frequency of readmission following bariatric surgery. We have utilized the Bariatric Outcomes Longitudinal Database (BOLD), the largest prospective database of bariatric patient outcomes worldwide, to identify predictors of serious postoperative complications requiring hospital readmission within 30 days of discharge.

Methods {#s2}
=======

Design Overview {#s2a}
---------------

We obtained patient data from BOLD collected between January 1, 2007 and August 31, 2009 at 450 Bariatric Surgery Centers of Excellence (BSCOE). Data collection for BOLD was overseen by the Surgical Review Corporation (SRC). Written informed consent was obtained from all patients, and the protocols of this study were approved by the University of Minnesota institutional review board.

The American Society for Metabolic and Bariatric Surgery (ASMBS) founded SRC in 2003 as an independent, nonprofit research organization to oversee compliance and collect data on patient outcomes for accredited BSCOE hospitals. The criteria set forth by the ASMBS for BSCOE certification include: performing at least 125 bariatric surgeries per year in hospitals or 100 bariatric surgeries per year in surgery centers; surgeons must have completed 125 bariatric surgeries during their career and must continue to perform at least 50 bariatric surgeries per year; a multidisciplinary staff including a team of nurses, surgeons, dieticians and other consultants; onsite inspections of BSCOE must be performed every three years; and, hospitals must report their outcomes to the BOLD database.

BOLD, an internet-based database implemented in 2007, represents the largest repository of clinical bariatric patient surgery information in the world with 521 contributing BSCOE. BOLD collects standardized assessments of patient demographics, preoperative morbidities, medication use, surgical procedures, and post-surgical follow-up visits. Additional details regarding the operational procedures of BOLD have been reported previously [@pone.0032506-DeMaria1]. Standard protocol for BSCOE requests that patients return to their operating physician for periodic follow-up visits including at least one visit one month post-operatively. At each follow-up visit, visit-specific information is recorded into BOLD on weight, complications, and readmissions since the previous follow-up visit regardless of whether the readmitting hospital was BSCOE-certified.

Setting and Participants {#s2b}
------------------------

Enrollment and data entry for BOLD is ongoing, though we excluded surgeries which took place after August 31, 2009 to ensure that all patients had adequate opportunity to follow-up with their surgical center and BSCOE had sufficient time to submit patient data as of the most recent database closing on March 1, 2010. For each patient in the study, we extracted complete data on demographic information, comorbidities, inpatient data, and post-surgical follow-up, including data on readmissions, complications, and mortality. Self-reported data on demographics and comorbid conditions were complete for nearly all patients and suspect data entry errors were rare. Suspect BMI values were replaced with data from an alternate visit. Patients were eligible for inclusion if they underwent a non-revision RYGB or AGB and had complete follow-up through at least 30 days following discharge.

The 30-day follow-up rate among BOLD participants was 91.6% during the study period, however follow-up rates were variable across BSCOE. Analysis of the within-BSCOE relationship between the follow-up rate and readmission rate indicated that centers with lower follow-up rates tended to report lower readmission rates, suggesting that centers with lower follow-up rates underreported their true readmission rates. To ensure high accuracy of outcomes reporting, we excluded BSCOE reporting complete 30-day outcome data for fewer than 90% of their surgical patients. Statistically significant differences between patients from included and excluded BSCOE were observed for several baseline characteristics due to the large sample sizes and correspondingly small standard errors, but these differences were small in magnitude and not clinically relevant. Sensitivity analyses on the effect of restricting participants to highly compliant BSCOE were performed on the readmission and mortality rates under a wide variety of assumptions, but had little effect on the rates due to the relative rarity of the outcome.

Outcomes and Follow-up {#s2c}
----------------------

Predictors of interest were demographic, health, and surgical variables. Clinical definitions of comorbid conditions are presented in [Table 1](#pone-0032506-t001){ref-type="table"}. Prolonged length of stay was defined as a hospital stay ≥4 days for laparoscopic RYGB, ≥6 days for open RYGB and ≥2 days for AGB. Our outcome was all-cause hospital readmission within 30 days of discharge requiring hospitalization for \>23 hours. We considered patients to be at risk for readmission on the day of discharge. No serious intraoperative complications requiring additional hospitalization were classified as readmissions. Patients were considered at risk for mortality on the day of surgery. Patients who were readmitted and died in the hospital within 30 days of surgery were classified as both readmissions and mortalities; patients who died outside a hospital were classified as mortalities but not readmissions.

10.1371/journal.pone.0032506.t001

###### Clinical definitions of pre-existing conditions.

![](pone.0032506.t001){#pone-0032506-t001-1}

  Condition                                                                                     Clinical Definition
  ---------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------
  Abdominal hernia                                                          Any history of symptomatic or asymptomatic abdominal hernia
  Abdominal/skin pannus                     Any current symptoms, including intertriginous irritation, interfering with ambulation, recurrent cellulitis, or ulceration
  Alcohol use                                                                                 Any current alcohol use
  Angina                                                                      Any chest pain symptoms or angina regardless of exertion
  Asthma                                                                       Any symptoms of asthma regardless of medication usage
  Back pain                                                 Has degenerative changes or positive objective findings, symptoms require narcotic treatment
  Bipolar disorder                                                                    Confirmed diagnosis of bipolar disorder
  Cholelithiasis                                                        Has had gallstones with severe symptoms or has had a cholecystectomy
  Congestive heart failure                                         Any history or symptoms of congestive heart failure (Class I, II, III, and IV)
  Depression                                           At least moderate depression with significant impairment, undergoing medical or therapeutic treatment
  DVT/PE                                                         Any history of resolved or recurrent deep venous thrombosis or pulmonary embolism
  Fibromyalgia                                                                               Any degree of fibromyalgia
  Gastroesophageal reflux disease                      Symptoms require the use of medical treatment (at least H2 blockers or low-dose proton pump inhibitor)
  Gout/hyperuricemia                                                           Has at least symptomatic or asymptomatic hyperuricemia
  Hypertension                                                                  Requires medical treatment with multiple medications
  Ischemic heart disease                        Has at least abnormal electrocardiogram, regardless of active ischemia; may include history of myocardial infarction
  Lipids                                                                    Heightened cholesterol requiring at least single medication
  Liver disease                                                Any history of liver disease, including hepatomegaly or non-normal liver function test
  Lower extremity edema                                                   Has symptoms requiring treatment, diuretics, elevation, or hose
  Musculoskeletal disease                                  Has pain with household ambulation, requires surgical intervention, or past joint replacement
  Obesity hypoventilation syndrome                                          Any symptoms including hypoxemia or hypercarbia on room air
  Obstructive sleep apnea                                          Sleep apnea requiring oral appliance, significant hypoxia, or oxygen-dependent
  Panic disorder                                                                       Confirmed diagnosis of panic disorder
  Peripheral vascular disease                                                       Any symptoms of peripheral vascular disease
  Personality disorder                                                              Confirmed diagnosis of personality disorder
  Psychosocial impairment                                      Any indicated psychosocial impairment, regardless of ability to perform primary tasks
  Pseudotumor cerebri                 Any symptoms of pseudotumor cerebri (at least headaches with dizziness, nausea, or pain behind the eyes) with or without visual symptoms
  Psychosis                                                                               Confirmed diagnosis of psychosis
  Pulmonary hypertension                                   Any symptoms associated with pulmonary hypertension (shortness of breath, dizziness, fainting)
  Substance abuse                                                                            Any recent substance abuse
  Stress urinary incontinence                                               Frequent stress urinary incontinence, regardless of severity
  Tobacco use                                                                                  Any recent tobacco use
  Type-2 diabetes                                                                            Diabetes requiring insulin

Abbreviations: DVT, deep venous thrombosis; PE, pulmonary embolism.

Statistical Analysis {#s2d}
--------------------

The demographic characteristics and medical histories of patients undergoing the two surgeries were compared with *t*-tests for continuous variables and chi-square tests for categorical variables, and Fisher\'s exact tests for rare counts. Risk factors for readmission were evaluated using a series of generalized linear mixed-effects models. Demographic, health, and surgical covariates were estimated as fixed effects and a random effect was estimated for BSCOE to account for variation between and correlation within BSCOE in their readmission rates. Those covariates significantly associated with readmission in univariate analysis at a significance level of 0.10 or greater were entered into a multivariate model with an iterative backward selection procedure that continued until all variables were significant at the 0.10 level.

We used expanded mixed-effects logistic models with interactions to examine mediation of risk factors by surgical approach. Readmission risk was higher among open surgeries, however the risk factors for open and laparoscopic RYGB approaches were not significantly different in the expanded models, so we controlled for the higher rate of readmission among open procedures with an additional fixed effect and did not stratify models by surgical approach. All *P* values are two-sided and are unadjusted for multiple comparisons. Statistical analyses were conducted in SAS version 9.2 (SAS Institute Inc., Cary, North Carolina) and graphs were generated in R version 2.14.0 (R Development Core Team, 2011).

Results {#s3}
=======

Patients {#s3a}
--------

[Figure 1](#pone-0032506-g001){ref-type="fig"} details the patient selection process. Among BSCOE eligible for analysis, 24,662 RYGB patients from 249 BSCOE and 26,002 AGB patients from 317 BSCOE were followed-up at 30 days. Bariatric surgery patients had a mean age of 45.9±11.9 years and were predominantly female (78.9%) and Caucasian (80.1%). Patients undergoing RYGB had higher BMI and higher prevalence of comorbidities than patients who underwent AGB ([Table 2](#pone-0032506-t002){ref-type="table"}). The laparoscopic approach was employed for 90.7% of RYGB and 99.7% of AGB operations. Prior to discharge, 1,728 (7.7%) laparoscopic RYGB patients, 159 (7.0%) open RYGB patients, and 1,183 AGB patients (4.6%) had a prolonged length of stay.

![Flow diagram of patient selection.](pone.0032506.g001){#pone-0032506-g001}

10.1371/journal.pone.0032506.t002

###### Characteristics of Study Participants by Surgery.
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                                         Roux-en-Y Gastric Bypass   Adjustable Gastric Banding  
  ------------------------------------- -------------------------- ---------------------------- ---------
  Demographics                                                                                  
  Age                                          45.7 (11.6)                 46.1 (12.1)           \<0.001
  Female sex                                  19,259 (78.1)               20,736 (79.8)          \<0.001
  Black race                                    2265 (9.2)                 2890 (11.1)           \<0.001
  Caucasian race                              19,973 (81.0)               20,590 (79.2)          \<0.001
  Disabled                                      2140 (8.7)                  1192 (4.6)           \<0.001
  Private insurance                           20,878 (84.7)               21,478 (82.6)          \<0.001
  Medicare/Medicaid                            2919 (11.8)                  2148 (8.6)           \<0.001
  Medical history                                                                               
  BMI[b](#nt104){ref-type="table-fn"}           47.2 (8.3)                  44.2 (6.7)           \<0.001
  Number of medications                         3.8 (4.0)                   2.8 (3.5)            \<0.001
  Comorbidities                                                                                 
  Abdominal hernia                              1379 (5.6)                  1032 (4.0)           \<0.001
  Abdominal/skin pannus                         2097 (8.5)                  1081 (4.2)           \<0.001
  Alcohol use                                  7469 (30.3)                 7194 (27.7)           \<0.001
  Angina                                        914 (3.7)                   576 (2.2)            \<0.001
  Asthma                                       3312 (13.4)                 2707 (10.4)           \<0.001
  Back pain                                    2629 (10.7)                  1926 (7.4)           \<0.001
  Bipolar disorder                              490 (2.0)                   350 (1.4)            \<0.001
  Cholelithiasis                               4614 (18.7)                 3843 (14.8)           \<0.001
  Congestive heart failure                      703 (2.9)                   435 (1.7)            \<0.001
  Depression                                   3589 (14.6)                 3065 (11.8)           \<0.001
  DVT/PE                                        937 (3.8)                   850 (3.3)             0.001
  Fibromyalgia                                  908 (3.7)                   694 (2.7)            \<0.001
  GERD                                         6473 (26.3)                 5629 (21.7)           \<0.001
  Gout/hyperuricemia                            1006 (4.1)                  644 (2.5)            \<0.001
  Hypertension                                 5850 (23.7)                 5051 (19.4)           \<0.001
  Ischemic heart disease                        1299 (5.3)                  1152 (4.4)           \<0.001
  Lipids                                       6750 (27.4)                 6015 (23.1)           \<0.001
  Liver disease                                 2160 (8.8)                  1102 (4.2)           \<0.001
  Lower extremity edema                        3138 (12.7)                  2342 (9.0)           \<0.001
  Musculoskeletal disease                      2637 (10.7)                  2137 (8.2)           \<0.001
  Obesity hypoventilation syndrome              578 (2.3)                   506 (2.0)             0.002
  Obstructive sleep apnea                      7424 (30.1)                 5811 (22.4)           \<0.001
  Panic disorder                                2073 (8.4)                  1520 (5.9)           \<0.001
  Peripheral vascular disease                   327 (1.3)                   227 (0.9)            \<0.001
  Personality disorder                          189 (0.8)                    59 (0.2)            \<0.001
  Psychosocial impairment                      4321 (17.5)                 3040 (11.7)           \<0.001
  Pseudotumor cerebri                           446 (1.8)                   278 (1.1)            \<0.001
  Psychosis                                      23 (0.1)                    15 (0.1)             0.15
  Pulmonary hypertension                        1430 (5.8)                  1051 (4.0)           \<0.001
  Substance abuse                               105 (0.4)                    71 (0.3)             0.004
  Stress urinary incontinence                  2859 (11.6)                 2692 (10.4)           \<0.001
  Tobacco use                                   1805 (7.3)                  1748 (6.7)            0.009
  Type-2 diabetes requiring insulin            3029 (12.3)                  2030 (7.8)           \<0.001

Abbreviations: BSCOE, bariatric surgery center of excellence; DVT, deep venous thrombosis; GERD, gastroesophageal reflux disease; PE, pulmonary embolism.

*P* values calculated using *t*-tests for continuous variables and Pearson\'s chi-squared tests or Fisher\'s exact tests for categorical variables.

Body mass index (BMI) was calculated as weight in kilograms divided by height in meters squared.

Readmission and mortality {#s3b}
-------------------------

In the first 30 days after discharge, 1437 (5.8%) RYGB patients and 322 (1.2%) AGB patients were readmitted ([Figure 2](#pone-0032506-g002){ref-type="fig"}; *P*\<0.001 for difference). Patients undergoing RYGB procedures with the laparoscopic approach had fewer readmissions than patients who underwent RYGB with an open approach (5.6% v. 7.9%, *P*\<0.001). The most commonly reported complications at readmission were nausea/vomiting and dehydration for both procedures, though more than one reason could be recorded for a readmission ([Table 3](#pone-0032506-t003){ref-type="table"}). For RYGB, other common complications at readmission were gastrointestinal bleeding, stricture, and obstruction; pneumonia, device-related infection, and obstruction were common complications reported at AGB readmissions.

![Cumulative incidence of 30-day readmission by surgery.](pone.0032506.g002){#pone-0032506-g002}

Within the 30 days of the primary operation, 35 (0.14%) RYGB patients and 6 (0.02%) AGB patients died (*P*\<0.001 for difference). For RYGB patients, causes of mortality were sepsis (n = 11), cardiac failure (n = 6), myocardial infarction (n = 4) respiratory failure (n = 4), stroke (n = 2), pulmonary embolus (n = 1), or could not be determined (n = 6). For AGB patients, causes of death were myocardial infarction (n = 3) or indeterminate (n = 3).

10.1371/journal.pone.0032506.t003

###### Common Complications at Readmission by Surgery.
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                             Roux-en-Y Gastric Bypass    Adjustable Gastric Banding                               
  ------------------------- --------------------------- ---------------------------- ---------------------------- -----------
                                  Nausea/vomiting                346 (24.1)                Nausea/vomiting         57 (17.7)
                                    Dehydration                  170 (11.8)                  Dehydration           37 (11.5)
                             Gastrointestinal bleeding            82 (5.7)             Device-related infection    27 (8.4)
                                     Stricture                    79 (5.5)            Device-related obstruction   18 (5.6)
                              (Internal) obstruction              76 (5.3)                    Pneumonia            13 (4.0)
                                Anastomotic leakage               58 (4.0)                Wound complication       13 (4.0)
                                Wound complications               52 (3.6)            Device-related intolerance   12 (3.7)
                              Intra-abdominal abscess             52 (3.6)              Deep venous thrombosis     11 (3.4)
  30-day readmission rate                                        1437 (5.8)                                        322 (1.2)
  30-day mortality rate                                          35 (0.14)                                         6 (0.02)

BSCOE could report more than one complication at readmission, so the reported percentages reflect the proportion of all readmissions involving those complications. This table lists the eight most-reported complications per surgery and does not add to 100%. A device-related obstruction was a complication of the device causing intestinal obstruction, whereas device-related intolerance is an unspecified complication due the device, implant, and graft.

Predictors of readmission {#s3c}
-------------------------

[Table 4](#pone-0032506-t004){ref-type="table"} presents univariate and multivariate risk factor analyses for readmission. After adjusting for other significant covariates, prolonged length of stay more than doubled the odds of readmission for a RYGB patient and the open surgical approach nearly doubled odds of readmission. Patients with current symptoms of clinical depression or psychosocial impairment, peripheral vascular disease, pseudotumor cerebri, or those with a previous history of gallstones or cholecystecomy were more likely to be readmitted than those without those symptoms. The number of medications used preoperatively was also associated with higher readmission rates, and an African-American patient had 34% higher odds of readmission compared to a Caucasian individual holding other factors constant.

10.1371/journal.pone.0032506.t004

###### Univariate and Multivariate Models of Risk Factors for 30-Day All-Cause Hospital Readmission by Surgery.
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                                             Roux-en-Y Gastric Bypass   Adjustable Gastric Banding                       
  ----------------------------------------- -------------------------- ---------------------------- -------------------- -------------------
  Age (5 years)                                 1.00 (0.98--1.03)                   \-               1.11 (1.06--1.17)           \-
  Male gender                                   0.94 (0.83--1.08)                   \-               1.68 (1.32--2.14)    1.45 (1.12--1.87)
  Race (ref. Caucasian)                                                                                                  
  Black/African American                        1.32 (1.10--1.58)           1.34 (1.11--1.62)        0.63 (0.41--0.97)           \-
  Hispanic/Latino                               1.01 (0.77--1.31)           1.05 (0.81--1.38)        0.97 (0.55--1.70)           \-
  Other                                         1.06 (0.74--1.51)           1.07 (0.74--1.53)        0.83 (0.44--1.55)           \-
  ASA classification^a^ (ref. "1")                                                                                       
  2/3 -- mild systemic disease                  1.45 (0.81--2.61)                   \-               1.64 (0.77--3.47)    1.41 (0.66--2.99)
  4/5 -- severe disease                         2.23 (1.20--4.16)                   \-               4.49 (1.88--10.7)    2.44 (1.01--5.89)
  BMI^b^ (ref. 45--49.9)                                                                                                 
  30--34.9                                      1.07 (0.71--1.61)                   \-               0.81 (0.42--1.57)           \-
  35--39.9                                      1.02 (0.86--1.22)                   \-               1.25 (0.88--1.78)           \-
  40--44.9                                      0.98 (0.84--1.15)                   \-               1.19 (0.84--1.67)           \-
  50--54.9                                      1.12 (0.94--1.35)                   \-               1.48 (0.96--2.29)           \-
  55--59.9                                      1.15 (0.91--1.46)                   \-               1.93 (1.11--3.33)           \-
  60+                                           1.35 (1.10--1.66)                   \-               2.52 (1.47--4.33)           \-
  Employment status (ref. Employed)                                                                                      
  Disabled                                      1.55 (1.30--1.85)                   \-               2.82 (1.95--4.09)    1.79 (1.21--2.65)
  Retired                                       1.18 (0.96--1.45)                   \-               1.98 (1.43--2.73)    1.43 (1.02--2.01)
  Unemployed                                    1.26 (1.03--1.53)                   \-               1.15 (0.68--1.93)    1.02 (0.60--1.72)
  Payment method (ref. private insurance)                                                                                
  Self-payer                                    0.67 (0.46--0.97)           0.69 (0.48--1.01)        1.10 (0.72--1.69)           \-
  Medicare/Medicaid                             1.46 (1.24--1.70)           1.12 (0.95--1.32)        2.22 (1.63--3.03)           \-
  Number of medications (5 med interval)        1.25 (1.17--1.34)           1.10 (1.02--1.19)        1.50 (1.30--1.72)           \-
  Open surgical method                          1.93 (1.56--2.39)           1.78 (1.44--2.20)        2.48 (0.59--10.37)          \-
  Prolonged length of stay                      2.47 (2.11--2.89)           2.28 (1.95--2.68)        3.08 (2.19--4.33)    2.32 (1.63--3.30)
  Comorbidities                                                                                                          
  Alcohol use                                   0.76 (0.66--0.87)           0.82 (0.71--0.94)        0.83 (0.63--1.08)           \-
  Angina                                        1.41 (1.09--1.83)                   \-               2.35 (1.43--3.85)    1.58 (0.95--2.63)
  Asthma                                        1.26 (1.09--1.46)                   \-               1.77 (1.32--2.37)    1.52 (1.12--2.05)
  Cholelithiasis                                1.29 (1.13--1.48)           1.18 (1.03--1.36)        1.25 (0.93--1.68)           \-
  Depression                                    1.34 (1.15--1.56)           1.18 (1.01--1.39)        1.18 (0.85--1.65)           \-
  DVT/PE                                        1.49 (1.17--1.91)           1.24 (0.96--1.60)        2.79 (1.78--4.37)    2.09 (1.32--3.29)
  GERD                                          1.22 (1.08--1.38)                   \-               1.54 (1.20--1.97)    1.30 (1.01--1.68)
  Ischemic heart disease                        1.49 (1.21--1.83)           1.21 (0.97--1.51)        1.86 (1.24--2.79)           \-
  Lower extremity edema                         1.24 (1.06--1.45)                   \-               1.98 (1.45--1.90)    1.36 (0.99--1.89)
  Obstructive sleep apnea                       1.10 (0.98--1.24)                   \-               1.97 (1.56--2.49)    1.45 (1.13--1.87)
  Psychosocial impairment                       1.36 (1.17--1.57)           1.19 (1.02--1.39)        0.97 (0.69--1.38)           \-
  Pseudotumor cerebri                           1.75 (1.20--2.55)           1.63 (1.11--2.39)        1.82 (0.79--4.22)           \-
  Peripheral vascular disease                   1.78 (1.23--2.57)           1.44 (0.99--2.11)        1.28 (0.47--3.50)           \-

Abbreviations: ASA, American Society of Anesthesiologists; CI, confidence interval; DVT, deep venous thrombosis; GERD, gastroesophageal reflux disease; OR, odds ratio; PE, pulmonary embolism. Ref denotes the reference group of a categorical variable. The variables for participation of surgical resident, COE volume, abdominal hernia, abdominal pannus, back pain, bipolar disorder, congestive heart failure, fibromyalgia, gout/hyperuricemia, hypertension, lipids, liver disease, musculoskeletal disease, obesity hypoventilation syndrome, panic disorder, personality disorder, psychosis, pulmonary hypertension, substance abuse, stress urinary incontinence, and type-2 diabetes were not significant at *P*≤.10 in univariate analysis and/or not significant in either multivariate model for either surgery and are not shown. Dashes indicate that the variable was not included in the multivariate model because it was removed either for not meeting the significance threshold in the univariate model or for being removed in the backwards selection procedure.

For AGB, prolonged length of stay also doubled a patient\'s odds of readmission. Male patients had nearly 50% greater odds of readmission than female patients, and disabled and retired employment statuses were more likely to have been readmitted than employed individuals after controlling for other significant demographic and health factors. Patients undergoing AGB with symptomatic asthma, gastroesophageal reflux disease (GERD), obstructive sleep apnea (OSA), or a history of deep venous thrombosis or pulmonary embolism (DVT/PE) had significantly higher odds of being readmitted within 30 days compared to patients without those medical complications.

Discussion {#s4}
==========

The overall reduction in mortality and the resolution of chronic diseases such as type 2 diabetes are substantial following bariatric surgery [@pone.0032506-Adams1]--[@pone.0032506-Vetter1]. However, the potential for serious complications is a barrier for patients and payers to utilizing the long-term advantages offered by bariatric surgery. The penalizing of hospitals for early readmissions is already underway, and several states are imposing mandates that call for further reductions in readmissions. Primary care providers and surgeons alike will see substantial decreases in reimbursements for readmitted patients, and it is therefore imperative that systems be in place to prevent the occurrence of readmissions. In this study, we have identified factors predictive of severe events requiring hospital readmission within 30 days of RYGB or AGB in the largest prospective bariatric cohort to date and have established that short-term risk for readmission is low for both procedures and risk profiles are largely unique to each procedure.

We observed a RYGB readmission rate nearly five times higher than AGB. Previously reported hospital readmission rates for bariatric surgery vary widely in the literature [@pone.0032506-Zingmond1], [@pone.0032506-Encinosa1], [@pone.0032506-Birkmeyer1]--[@pone.0032506-Weller2]. Possible explanations for these disparities may be due to differences in the patient populations, the definition of a hospital readmission, the proportion of patients within a sample undergoing open versus laparoscopic procedures, or surgeon experience.

The higher readmission and mortality rates for RYGB relative to AGB might suggest that AGB is preferable, however such risks must be weighed with the treatment outcomes. RYGB has been shown to result in greater weight loss and superior improvement in comorbid illness [@pone.0032506-Dorman2], [@pone.0032506-Nguyen1]--[@pone.0032506-Maggard1]. Our group recently reported on greater one-year improvements among patients with type 2 diabetes with respect to weight loss, hemoglobin A~1~C, medication scores, and rates of diabetes resolution for RYGB patients compared to matched AGB controls [@pone.0032506-Dorman2]. Short-term complications must be weighed against the long-term benefits and complications of each procedure.

The clearest predictors of readmission following RYGB were the use of the open surgical approach and prolonged length of stay. While open procedures are justified for certain complex cases [@pone.0032506-Puzziferri1], our results, when considered with previous research [@pone.0032506-Hutter1], suggest that laparoscopic techniques should be preferred to open surgery in the absence of contraindications for laparoscopy. Patients with previous histories of bariatric surgery or other anatomical abnormalities may be best suited for open surgeries and would understandably be at higher risk for readmission. However, 7.6% of hospitals (19 of 249 BSCOE) conducted \>80% of their RYGB procedures using the open approach and accounted for 46.6% of all open procedures in the database, suggesting that the open approach may be often dictated by surgeon preference in these hospitals rather than case difficulty.

The influence of serious comorbid disease on readmission risk for RYGB patients is expected, though the causal pathway of elevated risk for African-Americans is less clear. We suspect that the association with race may have been confounded by unmeasured variables such as surgical preparation, social support, economic status, or dietary intake. For AGB, readmission risk factors were quite different from those identified with RYGB with the exception of prolonged length of stay and severe ASA score: disability status, asthma, male gender, history of DVT/PE, and the presence of OSA or GERD.

Surprisingly, the profiles of risk factors for readmission were almost entirely distinct for the AGB and RYGB procedures. Prolonged length of stay following surgery was one of the only factors that significantly predicted readmissions in both surgical populations in multivariate analysis. That procedure-specific risk factors contrast so greatly between the two procedures is an important finding potentially overlooked by prior investigations. Previous studies have chosen to pool patients across procedures for analysis assuming that the underlying risk factors were the same [@pone.0032506-Flum1], [@pone.0032506-Gupta1]. While several of our results are complementary, the choice to aggregate surgical patients may account for some important differences in results. Some previous studies examining readmission rates have identified high BMI as a risk factor for readmission [@pone.0032506-Flum1], [@pone.0032506-Kellogg1], while our own did not. Risk analyses that pooled patients from multiple procedures may have observed an artificial inflation of risk for high-BMI patients who tend to undergo RYGB, which has a significantly higher readmission rate than AGB. The relationship between BMI and readmission risk may also have been confounded by a less complete comorbidity profile in risk models, since many conditions are more prevalent among individuals of greater weight. The ability to examine the role of a very extensive list of comorbidities is a major strength of this analysis.

Many of the identified risk factors, while complex, multifactorial, and often not necessarily modifiable, provide an impetus to follow patients at higher risk for readmission more aggressively following discharge. Prolonged length of stay, for example, was identified as an important risk factor yet the reasons for the longer stay varied widely in BOLD; both preoperative and perioperative factors can interact to influence the duration of a patient\'s stay. Despite this heterogeneity, prolonged length of stay could be utilized as a prompt for enhanced post-discharge monitoring in patients at higher risk for readmission. Intervention studies are needed to determine if and how enhanced monitoring, adjunctive treatments, or additional education might reduce readmission rates for high-risk patients. Certainly, enhanced monitoring is unlikely to prevent more serious readmissions such as those in patients who develop gastrointestinal leaks or obstructions. Further, it is unknown at this time how much effort would need to be applied to significantly lower the current readmission rates that are already acceptably low. However, it may be possible to impact the most prevalent reasons for readmission, nausea and vomiting, by establishing infusion centers for patients suffering from a slow return of bowel function and dehydration.

It is important to recognize the magnitude of relative risk differences associated with the predictors of readmission in this analysis; primarily, comorbid conditions must be weighed with the absolute risk for each procedure. For example, a relative risk of 1.5 for a high-risk patient group compared to a group of typical patients would equate to an increase of the readmission rate from 5.8% to 8.7% for RYGB and from 1.2% to 1.8% for AGB, or absolute risk differences of 2.9% and 0.6%, respectively. Patients, payers, and practitioners alike may find these higher risks acceptable if outweighed by the benefits of surgery, which are often greatest among patients with more severe comorbidity profiles. For these reasons, we deem that the current results do not support patient selection, but rather highlight patient groups that could benefit from appropriate preventative or educational efforts, and possibly, closer post-discharge follow-up.

This study has several limitations. The exclusion of centers with low follow-up rates is the most important limitation, since it is possible that BSCOE excluded for low follow-up rates may have been the hospitals with the highest readmission rates, as well. Our sensitivity analyses comparing included and excluded centers did not indicate that there were substantive clinical differences between the patient populations ([Tables 5](#pone-0032506-t005){ref-type="table"} and [6](#pone-0032506-t006){ref-type="table"}), and if such a bias were present, it is highly unlikely that an underestimation of readmission rates would have a considerable impact on the strength or direction of the risk factors themselves. Long-term follow-up in BOLD was limited and precluded the examination of readmissions occurring beyond 30 days. RYGB patients continue to require readmission up to and beyond one year, and the need for band revisions generally do not occur within the first 30 days of surgery; however, the greatest proportion of readmissions occur within 30 days [@pone.0032506-Kellogg1], [@pone.0032506-Saunders1], so the current study likely captures the most important risk factors for readmission.

10.1371/journal.pone.0032506.t005

###### Comparison of RYGB Patients from Included and Excluded BSCOE.

![](pone.0032506.t005){#pone-0032506-t005-5}

                                         Included BSCOE   Excluded BSCOE  
  ------------------------------------- ---------------- ---------------- ---------
  BSCOE                                    249 (55.5)       200 (44.5)       \-
  Age                                     45.6 (11.6)      45.1 (11.5)     \<0.001
  Female sex                             20,162 (77.9)    17,051 (78.7)     0.04
  Race                                                                     \<0.001
  Black                                    2406 (9.3)      2373 (11.0)    
  Caucasian                              20,909 (80.8)    15,808 (73.0)   
  Hispanic/Latino                          1789 (6.9)       1799 (8.3)    
  Other                                    773 (3.0)        1684 (7.8)    
  ASA Classification                                                       \<0.001
  1 -- normal, healthy                     338 (1.3)        1337 (6.2)    
  2/3 -- mild systemic disease           24,072 (93.0)    19,276 (89.0)   
  4/5 -- severe/very severe disease        1467 (5.7)       1051 (4.9)    
  BMI[b](#nt109){ref-type="table-fn"}      47.2 (8.3)       47.3 (8.3)      0.37
  Employment status                                                        \<0.001
  Employed                               19,879 (76.8)    16,885 (77.9)   
  Disabled                                 2273 (8.8)       1680 (7.8)    
  Retired                                  1819 (7.0)       1425 (6.6)    
  Unemployed                               1906 (7.4)       1674 (7.7)    
  Payment Information                                                       0.10
  Private insurance                      21,876 (84.5)    18,467 (85.2)   
  Self-payer                               903 (3.5)        731 (3.4)     
  Medicare/Medicaid                       3098 (12.0)      2466 (11.4)    
  Number of medications                    3.8 (4.0)        3.2 (3.8)      \<0.001
  Comorbidities                                                           
  Abdominal hernia                         1456 (5.6)       939 (4.3)      \<0.001
  Abdominal/skin pannus                    2180 (8.4)       1111 (5.1)     \<0.001
  Alcohol use                             7798 (30.1)      6167 (28.5)     \<0.001
  Angina                                   976 (3.8)        488 (2.3)      \<0.001
  Asthma                                  3477 (13.4)      2903 (13.4)      0.91
  Back pain                               2754 (10.6)       1982 (9.2)     \<0.001
  Bipolar disorder                         521 (2.0)        446 (2.1)       0.74
  Cholelithiasis                          4836 (18.7)      3470 (16.0)     \<0.001
  Congestive heart failure                 751 (2.9)        437 (2.0)      \<0.001
  Depression                              3782 (14.6)      2890 (13.3)     \<0.001
  DVT/PE                                   971 (3.8)        612 (2.8)      \<0.001
  Fibromyalgia                             949 (3.7)        670 (3.1)      \<0.001
  GERD                                    6781 (26.2)      5073 (23.4)     \<0.001
  Gout/hyperuricemia                       1036 (4.0)       655 (3.0)      \<0.001
  Hypertension                            6115 (23.6)      4587 (21.2)     \<0.001
  Ischemic heart disease                   1374 (5.3)       917 (4.2)      \<0.001
  Lipids                                  7014 (27.1)      5562 (25.7)     \<0.001
  Liver disease                            2264 (8.8)       1091 (5.0)     \<0.001
  Lower extremity edema                   3287 (12.7)      2370 (10.9)     \<0.001
  Musculoskeletal disease                 2766 (10.7)      2319 (10.7)      0.96
  Obesity hypoventilation syndrome         608 (2.4)        525 (2.4)       0.60
  Obstructive sleep apnea                 7779 (30.1)      6474 (29.9)      0.67
  Panic disorder                           2175 (8.4)       1483 (6.9)     \<0.001
  Peripheral vascular disease              247 (1.3)        241 (1.1)       0.02
  Personality disorder                     196 (0.8)         52 (0.2)      \<0.001
  Psychosocial impairment                 4544 (11.6)      3138 (14.5)     \<0.001
  Pseudotumor cerebri                      467 (1.8)        635 (2.9)      \<0.001
  Psychosis                                 23 (0.1)         24 (0.1)       0.47
  Pulmonary hypertension                   1502 (5.8)       727 (3.4)      \<0.001
  Substance abuse                          111 (0.4)         96 (0.4)       0.83
  Stress urinary incontinence             2968 (11.5)      2683 (12.4)      0.002
  Tobacco use                              1910 (7.4)       1447 (6.7)      0.003
  Type-2 diabetes                         3172 (12.3)      2493 (11.5)      0.01

Abbreviations: BSCOE, bariatric surgery center of excellence; DVT, deep venous thrombosis; GERD, gastroesophageal reflux disease; PE, pulmonary embolism.

*P* values calculated using a *t*-test for continuous variables and Pearson\'s chi-squared test or Fisher\'s exact test for categorical variables.

Body mass index (BMI) was calculated as weight in kilograms divided by height in meters squared.

10.1371/journal.pone.0032506.t006

###### Comparison of AGB Patients from Included and Excluded BSCOE.

![](pone.0032506.t006){#pone-0032506-t006-6}

                                         Included BSCOE   Excluded BSCOE  
  ------------------------------------- ---------------- ---------------- ---------
  BSCOE                                    317 (68.3)       147 (31.7)       \-
  Age                                     46.1 (12.1)      46.5 (12.3)      0.01
  Female sex                             21,319 (79.7)     6919 (78.5)      0.02
  Race                                                                     \<0.001
  Black/African American                  2979 (11.1)       942 (10.7)    
  Caucasian                              21,171 (79.1)     6183 (70.2)    
  Hispanic/Latino                          1089 (4.1)       674 (7.7)     
  Other                                    1526 (5.7)      1015 (11.5)    
  ASA Classification                                                        0.004
  1 -- normal, healthy                     1388 (5.2)       381 (4.3)     
  2/3 -- mild systemic disease           24,635 (92.0)     8200 (93.0)    
  4/5 -- severe/very severe disease        742 (2.8)        233 (2.6)     
  BMI[b](#nt112){ref-type="table-fn"}      44.2 (6.7)       44.2 (7.2)      0.62
  Employment Status                                                        \<0.001
  Employed                               21,937 (82.0)     7132 (80.9)    
  Disabled                                 1240 (4.6)       527 (6.0)     
  Retired                                  2313 (8.6)       783 (8.9)     
  Unemployed                               1275 (4.8)       372 (4.2)     
  Payment Information                                                      \<0.001
  Private Insurance                      22,085 (82.5)     7169 (81.3)    
  Self-Payer                               2447 (9.1)       652 (7.4)     
  Medicare/Medicaid                        2233 (8.3)       993 (11.3)    
  Number of medications                    2.8 (3.5)        3.1 (3.5)      \<0.001
  Comorbidities                                                           
  Abdominal hernia                         1054 (3.9)       486 (5.5)      \<0.001
  Abdominal/Skin pannus                    1107 (4.1)       381 (4.3)       0.44
  Alcohol use                             7407 (27.7)      2750 (31.2)     \<0.001
  Angina                                   596 (2.2)        158 (1.8)       0.01
  Asthma                                  2788 (10.4)       893 (10.1)      0.45
  Back pain                                1999 (7.5)       626 (7.1)       0.25
  Bipolar disorder                         364 (1.4)        140 (1.6)       0.12
  Cholelithiasis                          3938 (14.7)      1146 (13.0)     \<0.001
  Congestive heart failure                 445 (1.7)        140 (1.6)       0.66
  Depression                              3144 (11.8)       767 (8.7)      \<0.001
  DVT/PE                                   878 (3.3)        218 (2.5)      \<0.001
  Fibromyalgia                             708 (2.7)        240 (2.7)       0.70
  GERD                                    5783 (21.6)      1563 (17.7)     \<0.001
  Gout/hyperuricemia                       661 (2.5)        414 (4.7)      \<0.001
  Hypertension                            5197 (19.4)      1693 (19.2)      0.67
  Ischemic heart disease                   1197 (4.5)       359 (4.1)       0.12
  Lipids                                  6192 (23.1)      2278 (25.9)     \<0.001
  Liver disease                            1151 (4.3)       438 (5.0)       0.008
  Lower extremity edema                    2413 (9.0)       671 (7.6)      \<0.001
  Musculoskeletal disease                  2219 (8.3)       814 (9.1)       0.02
  Obesity hypoventilation syndrome         517 (1.9)        150 (1.7)       0.17
  Obstructive sleep apnea                 5993 (22.4)      1931 (21.9)      0.34
  Panic disorder                           1567 (5.9)       541 (6.1)       0.33
  Peripheral vascular disease              234 (0.9)         89 (1.0)       0.24
  Personality disorder                      62 (0.2)         10 (0.1)       0.04
  Psychosocial impairment                 3145 (11.8)      1034 (11.7)      0.96
  Pseudotumor cerebri                      290 (1.1)         88 (1.0)       0.55
  Psychosis                                 15 (0.1)         6 (0.1)        0.62
  Pulmonary hypertension                   1084 (4.1)       167 (1.9)      \<0.001
  Substance abuse                           73 (0.3)         35 (0.4)       0.07
  Stress urinary incontinence             2748 (10.3)       833 (9.5)       0.03
  Tobacco use                              1813 (6.8)       568 (6.4)       0.28
  Type-2 diabetes                          2093 (7.8)       670 (7.6)       0.51

Abbreviations: BSCOE, bariatric surgery center of excellence; DVT, deep venous thrombosis; GERD, gastroesophageal reflux disease; PE, pulmonary embolism.

*P* values calculated using a *t*-test for continuous variables and Pearson\'s chi-squared test or Fisher\'s exact test for categorical variables.

Body mass index (BMI) was calculated as weight in kilograms divided by height in meters squared.

The present analysis was also unable to control for surgeon volume, an important factor in readmission [@pone.0032506-Birkmeyer1], [@pone.0032506-Weller1], [@pone.0032506-Weller2]. however surgeons reporting to BOLD must log over 50 cases annually in order to maintain BSCOE certification. Also, the distribution of readmission rates was not consistent with a uniform rate across centers ([Figures 3](#pone-0032506-g003){ref-type="fig"} and [4](#pone-0032506-g004){ref-type="fig"}). An appreciable number of BSCOE, for AGB in particular, reported readmission rates considerably lower than would be expected under a constant rate across centers of varying surgical volume. We suspect that unusually low BSCOE readmission rates reflect unmeasured variables such as surgical experience, and those with high rates of readmission could be indicative of either surgeon inexperience, case difficulty, or surgeon preference for open procedures. Data entered into BOLD is self-reported by BSCOE, so post-discharge events are potentially underreported in the database, though our selection of centers with high follow-up rates was undertaken to offset potential underreporting in the larger database.

![Loess plot of RYGB readmission rates on follow-up rates.\
Circles represent BSCOE hospitals with the size weighted by the number of patients who underwent the procedure in the hospital during the study period.](pone.0032506.g003){#pone-0032506-g003}

![Loess plot of AGB readmission rates on follow-up rates.\
Circles represent BSCOE hospitals with the size weighted by the number of patients who underwent the procedure in the hospital during the study period.](pone.0032506.g004){#pone-0032506-g004}

Finally, the observational nature of the study precludes causal inference about risk factors. Given that examination of factors influencing relatively rare events like readmissions requires thousands of patients to be adequately powered to assess differences in risk, it is unlikely that randomized studies of these factors will ever be performed. Therefore, decisions on patient selection and risk calculations will inevitably be based on large prospective observational databases like BOLD. Nested case-control studies, in which more extensive collection of possible explanatory variables is performed, may shed light on the problem of unmeasured confounders in the BOLD dataset.

In conclusion, we have characterized patterns of risk for readmission associated with patient and intraoperative factors for the two most common bariatric procedures in the largest prospective cohort of bariatric surgery patients to date. While the overall readmission rates for both procedures are low, the present results may prove to be an important clinical tool in the development of patient education programs, algorithms for procedure selection, and follow-up plans. In an effort to maximize patient benefit and cost-effectiveness of bariatric surgery and to reduce penalties from payers, primary care providers and surgeons should understand patient-specific risks to optimize clinical care for patients when both selecting for and immediately following their bariatric operation.
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